Lytispasm
Lytispasm Brand names, Lytispasm Analogs
Lytispasm Brand Names Mixture
- No information avaliable
Lytispasm Chemical_Formula
C17H32BrNO2
Lytispasm RX_link
No information avaliable
Lytispasm fda sheet
Lytispasm msds (material safety sheet)
Lytispasm Synthesis Reference
No information avaliable
Lytispasm Molecular Weight
362.346 g/mol
Lytispasm Melting Point
329 oC
Lytispasm H2O Solubility
1600 mg/L
Lytispasm State
Solid
Lytispasm LogP
0.60
Lytispasm Dosage Forms
Tablet (oral, 50mg)
Lytispasm Indication
For use in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying.
Lytispasm Pharmacology
Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
Lytispasm Absorption
Gastrointestinal absorption is poor and irregular. Total absorption after an oral dose is about 10 to 25%.
Lytispasm side effects and Toxicity
No information avaliable
Lytispasm Patient Information
Lytispasm Organisms Affected
Humans and other mammals
